LimFlow, Inc.
LimFlow was founded with the deep belief that more could be done for the millions of patients worldwide suffering from the most severe form of peripheral artery disease — Chronic Limb-Threatening Ischemia (CLTI) — and who are facing the prospect of amputation. Recognizing that angioplasty is only temporary in reducing symptoms and staving off amputation, and invasive bypass surgery has many drawbacks, the company founders sought a more permanent solution. By harnessing the concept of bypassing diseased arteries initially developed for the heart and applying it below-the-knee in a fully percutaneous procedure, LimFlow was born.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Globally (various continents)
About us
When peripheral artery disease (PAD) progresses to Chronic Limb-Threatening Ischemia (CLTI), a patient’s options become limited. As the disease evolves to its late stages, patients may no longer be candidates for balloons or stents and may face bypass surgery, or worse, amputation.
However, they are ready to do anything to resolve the pain and regain quality of life.
Enter LimFlow.
In a minimally-invasive fashion, the LimFlow System is designed to bypass blocked arteries in the leg and rush blood back into the foot, potentially avoiding major amputation, resolving pain and promoting wound healing.
The inventiveness of the company has led to a procedure that reimagines the anatomy, turning a vein into an artery and reversing flow to bring blood flow and oxygen back to starved ischemic legs.
The novel LimFlow System employs a variety of proprietary technologies — including ultrasound catheters, a push valvulotome, and crossing and extension stents — to create a new and minimally-invasive option for “no option” CLTI patients that may help them improve their lives and avoid amputation.